GeneQuine Selects Exothera to Support the Next Stage of Its Osteoarthritis Gene Therapy Development [ 09 Sep 2021 ]
GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, today announced that it has contracted Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), to conduct a feasibility study for the development of a large-scale manufacturing process for its osteoarthritis gene therapy product candidate GQ-303 in the highly scalable scale-X™ fixed-bed bioreactor.
GeneQuine Appoints Big Pharma Veteran Bernhard J. Kirschbaum to its Advisory Board [ 09 Jul 2021 ]
GeneQuine Biotherapeutics GmbH announces the appointment of Bernhard J. Kirschbaum, PhD to its advisory board. Dr. Kirschbaum, who will also be the chairman of GeneQuine’s advisory board, is a board member of several biotech companies. He has 20 years of experience in R&D of global international pharma companies at Hoechst Marion Roussel, Aventis, Sanofi-Aventis, and Merck Serono, and was in his last position Executive Vice President, Global Research & Early Development and member of the board at Merck Serono.
GeneQuine Biotherapeutics Secures More Than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases [ 26 Jan 2021 ]
.